Oxygenta Pharmaceutical Ltd Financials
Company Logo

Oxygenta Pharmaceutical Ltd Financial Statement

Oxygenta Pharmaceutical Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue49.52
Operating Expense51.42
Net Profit-2.15
Net Profit Margin-4.34
Earning Per Share-0.60
EBIDTA-0.09
Effective Tax Rate-8.42

Oxygenta Pharmaceutical Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual39.64
Operating Expenses Annual49.34
Operating Profit Annual-9.62
Interest Annual1.59
Depreciation2.66
Net Profit Annual-3.48
Tax Annual-10.39

Oxygenta Pharmaceutical Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.11
Cash Flow from Operations-13.05
Cash Flow from Investing-4.09
Cash Flow from Financing17.13
Cash Flow at the End0.10

Oxygenta Pharmaceutical Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)-24.27
PBIT Margin (%)-30.98
PBT Margin (%)-11.50
Net PROFIT Margin (%)-8.78
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-10.97
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)1.25

Oxygenta Pharmaceutical Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual29.36
Total Current Assets Annual24.11
Non Current Assets Annual39.09
Total Shareholders Funds Annual-20.12
Total Assets Annual63.19

Oxygenta Pharmaceutical Ltd Earning Calls

No Data Availabe

FAQS on Oxygenta Pharmaceutical Ltd Financials

As of Jun 1, 2025, Oxygenta Pharmaceutical Ltd has a market capitalization of 294.24 Cr. Value Research classifies it as a Small-Cap company.

Yes, Oxygenta Pharmaceutical Ltd is with a debt-to-equity ratio of -2.43.

In FY 2024 , Oxygenta Pharmaceutical Ltd recorded a total revenue of approximately 109.30 Cr marking a significant milestone in the company's financial performance.

Oxygenta Pharmaceutical Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.9% and 0.6% annually, respectively..

Oxygenta Pharmaceutical Ltd's current PE ratio is -28.57.

Oxygenta Pharmaceutical Ltd's ROCE averaged -35.7% from the FY ending March 2023 to 2025, with a median of -34.4%. It peaked at -33.1% in March 2024, reflecting strong capital efficiency over the period..

Oxygenta Pharmaceutical Ltd's latest EBIT is Rs. -12.57 Cr, surpassing the average EBIT of Rs. -11.58 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions